Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F182112 in Relapsed or Refractory Multiple Myeloma
NCT07579234Phase 3Recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of F182112 in multiple myeloma (MM), sponsored by Shandong New Time Pharmaceutical. Started Jan 2026; status: recruiting.
02
Drugs
F182112
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07579234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07579234.